Androgen replacement therapy for hypogonadism in advanced cancer patients
Not Applicable
- Conditions
- hypogonadism in avanced cancer
- Registration Number
- JPRN-UMIN000010939
- Lead Sponsor
- Kanazawa University, Department of Urology
- Brief Summary
The numbers of patients in the control and testosterone groups were 41 and 40, respectively. The testosterone group showed significant improvement in the unhappiness item of the Edmonton Symptom Assessment System at weeks 8 and 12. Serum tumor necrotic factor-alpha in the control group was significantly increased at week 12.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 106
Inclusion Criteria
Not provided
Exclusion Criteria
1. lrss than 20 year-old 2. prostate cancer or severe BPH 3. PSA>4ng/ml and patients who were thought as inadequate for this study by doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of QOL beween control group and ART group
- Secondary Outcome Measures
Name Time Method